## Edyta Pawlak-Adamska

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2579824/publications.pdf

Version: 2024-02-01

414414 471509 57 1,123 17 32 g-index citations h-index papers 60 60 60 1623 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Confirmation Bias in the Course of Instructed Reinforcement Learning in Schizophrenia-Spectrum Disorders. Brain Sciences, 2022, 12, 90.	2.3	2
2	The report and analysis concerning the usefulness of basic telemedicine tools in the skin cancer diagnostic screening process during COVID-19 pandemics. Postepy Dermatologii I Alergologii, 2022, 39, 189-194.	0.9	4
3	Socioeconomic aspect of breast cancer incidence and mortality in women in Lower Silesia (Poland) in 2005–2014. Postepy Higieny I Medycyny Doswiadczalnej, 2022, 76, 62-70.	0.1	O
4	The Moderating Role of the FKBP5 Gene Polymorphisms in the Relationship between Attachment Style, Perceived Stress and Psychotic-like Experiences in Non-Clinical Young Adults. Journal of Clinical Medicine, 2022, 11, 1614.	2.4	0
5	Regulation of ROCK1/2 by long non‑coding RNAs and circular RNAs in different cancer types (Review). Oncology Letters, 2022, 23, 159.	1.8	6
6	The Role of Dopaminergic Genes in Probabilistic Reinforcement Learning in Schizophrenia Spectrum Disorders. Brain Sciences, 2022, 12, 7.	2.3	6
7	Effects of traumatic life events, cognitive biases and variation in dopaminergic genes on psychosis proneness. Microbial Biotechnology, 2021, 15, 248-255.	1.7	8
8	The Impact of the FKBP5 Gene Polymorphisms on the Relationship between Traumatic Life Events and Psychotic-Like Experiences in Non-Clinical Adults. Brain Sciences, 2021, 11, 561.	2.3	3
9	Metallic Orthodontic Materials Induce Gene Expression and Protein Synthesis of Metallothioneins. Materials, 2021, 14, 1922.	2.9	2
10	NF-κB1 -94del/del ATTG polymorphic variant maintains CLL at an early, mildest stage. Advances in Clinical and Experimental Medicine, 2021, 30, 499-506.	1.4	0
11	Effects of variation in dopaminergic genes on the level of aggression and emotional intelligence in adolescents with conduct disorder. Archives of Psychiatry and Psychotherapy, 2021, 23, 15-23.	0.3	1
12	Deregulated Expression of Immune Checkpoints on Circulating CD4 T Cells May Complicate Clinical Outcome and Response to Treatment with Checkpoint Inhibitors in Multiple Myeloma Patients. International Journal of Molecular Sciences, 2021, 22, 9298.	4.1	8
13	Variation in gene encoding the co-inhibitory molecule BTLA is associated with survival in patients treated for clear cell renal carcinoma $\hat{a} \in \hat{a}$ results of a prospective cohort study. Archives of Medical Science, 2021, , .	0.9	O
14	The Significance of Toll-Like Receptors in the Neuroimmunologic Background of Alcohol Dependence. Frontiers in Psychiatry, 2021, 12, 797123.	2.6	3
15	Abnormal Expression of BTLA and CTLA-4 Immune Checkpoint Molecules in Chronic Lymphocytic Leukemia Patients. Journal of Immunology Research, 2020, 2020, 1-12.	2.2	20
16	Effects of interactions between variation in dopaminergic genes, traumatic life events, and anomalous self-experiences on psychosis proneness: Results from a cross-sectional study in a nonclinical sample. European Psychiatry, 2020, 63, e104.	0.2	7
17	Additive manufacturing technologies enabling rapid and interventional production of protective face shields and masks during the COVID-19 pandemic. Advances in Clinical and Experimental Medicine, 2020, 29, 1021-1028.	1.4	15
18	Paediatricâ€onset and adultâ€onset Graves' disease share multiple genetic risk factors. Clinical Endocrinology, 2019, 90, 320-327.	2.4	14

#	Article	IF	CITATIONS
19	Regulation of signaling pathways by Ampelopsin (Dihydromyricetin) in different cancers: exploring the highways and byways less travelled. Cellular and Molecular Biology, 2019, 65, 15.	0.9	1
20	Regulation of signaling pathways by Ampelopsin (Dihydromyricetin) in different cancers: exploring the highways and byways less travelled. Cellular and Molecular Biology, 2019, 65, 15-20.	0.9	1
21	Profiling inflammatory signatures of schizophrenia: A cross-sectional and meta-analysis study. Brain, Behavior, and Immunity, 2018, 71, 28-36.	4.1	115
22	Polymorphisms in immune-inflammatory response genes and the risk of deficit schizophrenia. Schizophrenia Research, 2018, 193, 359-363.	2.0	16
23	Epitopes identified in GAPDH from Clostridium difficile recognized as common antigens with potential autoimmunizing properties. Scientific Reports, 2018, 8, 13946.	3.3	8
24	The Influence of Genetic Variations in the CD86 Gene on the Outcome after Allogeneic Hematopoietic Stem Cell Transplantation. Journal of Immunology Research, 2018, 2018, 1-8.	2.2	3
25	Is the Genetic Background of Co-Stimulatory CD28/CTLA-4 Pathway the Risk Factor for Prostate Cancer?. Pathology and Oncology Research, 2017, 23, 837-843.	1.9	5
26	PD-1 gene polymorphic variation is linked with first symptom of disease and severity of relapsing-remitting form of MS. Journal of Neuroimmunology, 2017, 305, 115-127.	2.3	21
27	Targeting of EGFR Induced Signaling Network in Hepatocellular Carcinoma. , 2017, , 159-171.		O
28	Gender-dependent and age-of-onset-specific association of the rs11675434 single-nucleotide polymorphism near TPO with susceptibility to Graves' ophthalmopathy. Journal of Human Genetics, 2017, 62, 373-377.	2.3	14
29	CD28/CTLA-4/ICOS haplotypes confers susceptibility to Graves' disease and modulates clinical phenotype of disease. Endocrine, 2017, 55, 186-199.	2.3	27
30	Intragenic Variations in BTLA Gene Influence mRNA Expression of BTLA Gene in Chronic Lymphocytic Leukemia Patients and Confer Susceptibility to Chronic Lymphocytic Leukemia. Archivum Immunologiae Et Therapiae Experimentalis, 2016, 64, 137-145.	2.3	21
31	Interleukin-6: the missing element of the neurocognitive deterioration in schizophrenia? The focus on genetic underpinnings, cognitive impairment and clinical manifestation. European Archives of Psychiatry and Clinical Neuroscience, 2015, 265, 449-59.	3.2	95
32	Sex differences in TGFB-& TGFB-& signaling with respect to age of onset and cognitive functioning in schizophrenia. Neuropsychiatric Disease and Treatment, 2015, 11, 575.	2.2	24
33	A CT60G>A polymorphism in the CTLA-4 gene of the recipient may confer susceptibility to acute graft versus host disease after allogeneic hematopoietic stem cell transplantation. Immunogenetics, 2015, 67, 295-304.	2.4	13
34	<b><i>CTLA4</i></b> and <b><i>CD28</i></b> Gene Polymorphisms with Respect to Affective Symptom Domain in Schizophrenia. Neuropsychobiology, 2015, 71, 158-167.	1.9	8
35	Pretransplant donor and recipient CTLA-4 mRNA and protein levels as a prognostic marker for aGvHD in allogeneic hematopoietic stem cell transplantation. Immunology Letters, 2015, 165, 52-59.	2.5	7
36	Genetic polymorphisms and expression of <scp>HLA</scp> â€G and its receptors, <scp>KIR2DL4</scp> and <scp>LILRB1</scp> , in nonâ€small cell lung cancer. Tissue Antigens, 2015, 85, 466-475.	1.0	40

#	Article	IF	Citations
37	Polymorphisms in CD28, CTLA-4, CD80 and CD86 genes may influence the risk of multiple sclerosis and its age of onset. Journal of Neuroimmunology, 2015, 288, 79-86.	2.3	25
38	PPARg2 Ala12 variant protects against Graves' orbitopathy and modulates the course of the disease. Immunogenetics, 2013, 65, 493-500.	2.4	13
39	Genetic variants in transforming growth factor- $\hat{l}^2$ gene (TGFB1) affect susceptibility to schizophrenia. Molecular Biology Reports, 2013, 40, 5607-5614.	2.3	45
40	The role of genetic variations of immune system regulatory molecules CD28 and CTLA-4 in schizophrenia. Psychiatry Research, 2013, 208, 197-198.	3.3	13
41	Variations in Suppressor Molecule CTLA-4 Gene Are Related to Susceptibility to Multiple Myeloma in a Polish Population. Pathology and Oncology Research, 2012, 18, 219-226.	1.9	28
42	CTLA-4, CD28, and ICOS gene polymorphism associations with non-small-cell lung cancer. Human Immunology, 2011, 72, 947-954.	2.4	48
43	Donor CTLA-4 Gene Polymorphism Associations with Acute GvHD After Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2011, 118, 2010-2010.	1.4	O
44	Influence of CTLA-4/CD28/ICOS gene polymorphisms on the susceptibility to cervical squamous cell carcinoma and stage of differentiation in the Polish population. Human Immunology, 2010, 71, 195-200.	2.4	58
45	ICOS Gene Polymorphisms In B-Cell Chronic Lymphocytic Leukemia In a Polish Population Blood, 2010, 116, 4614-4614.	1.4	1
46	Soluble CTLA-4 receptor an immunological marker of Graves' disease and severity of ophthalmopathy is associated with CTLA-4 Jo31 and CT60 gene polymorphisms. European Journal of Endocrinology, 2009, 161, 787-793.	3.7	55
47	The <i>CTLAâ€4</i> gene polymorphisms are associated with CTLAâ€4 protein expression levels in multiple sclerosis patients and with susceptibility to disease. Immunology, 2009, 128, e787-96.	4.4	43
48	KIR Genes and Their HLA-C Ligands in B-Cell Chronic Lymphocytic Leukemia in a Polish Population Blood, 2009, 114, 4402-4402.	1.4	2
49	Association studies of CTLA-4, CD28, and ICOS gene polymorphisms with B-cell chronic lymphocytic leukemia in the Polish population. Human Immunology, 2008, 69, 193-201.	2.4	53
50	Cytotoxic T-Lymphocyte Associated Antigen 4 Gene Polymorphisms and Autoimmune Thyroid Disease: A Meta-Analysis. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 3162-3170.	3.6	162
51	Different patterns of activation markers expression and CD4+ T-cell responses to ex vivo stimulation in patients with clinically quiescent multiple sclerosis (MS). Journal of Neuroimmunology, 2007, 189, 137-146.	2.3	16
52	Alterations in the expression of signal-transducing CD3ζ chain in T cells from patients with chronic inflammatory/autoimmune diseases. Archivum Immunologiae Et Therapiae Experimentalis, 2007, 55, 373-386.	2.3	20
53	Gene Polymorphisms of Costimulatory Molecules: CTLA-4/CD28/ICOS Are Associated with B-Cell Chronic Lymphocytic Leukemia (B-CLL) Blood, 2007, 110, 2074-2074.	1.4	2
54	Association of T Cell Costimulatory and Downregulatory Gene Polymorphisms and Susceptibility to Multiple Myeloma Blood, 2006, 108, 5002-5002.	1.4	0

#	Article	IF	CITATIONS
55	The soluble CTLA-4 receptor: a new marker in autoimmune diseases. Archivum Immunologiae Et Therapiae Experimentalis, 2005, 53, 336-41.	2.3	18
56	Polymorphisms within genes encoding co-stimulatory molecules modulate the susceptibility to Graves' disease and orbitopathy. Endocrine Abstracts, 0, , .	0.0	0
57	The role of peroxisome proliferator-activated receptors [alpha] polymorphisms in Graves' disease and orbitopathy. Endocrine Abstracts, 0, , .	0.0	1